Sana Biotechnology (SANA) Corporate presentation summary

Transformative therapies for type 1 diabetes

• Type 1 diabetes affects about 10 million people globally, with significant unmet needs and reduced life expectancy despite current treatments.

• Hypoimmune islet cell technology enables insulin independence without immunosuppression, validated in preclinical and first-in-human studies.

• Clinical trial in a T1D patient showed cell survival, function, and immune evasion for over a year without adverse events.

• SC451, a stem cell-derived hypoimmune islet therapy, is advancing toward IND filing and Phase 1/2 trial initiation in 2026.

• Manufacturing, regulatory, and clinical site preparations are underway, with a focus on scalable, one-time therapy.

Hypoimmune technology and clinical validation

• Hypoimmune edits disrupt MHC I/II and overexpress CD47 to block immune rejection, enabling allogeneic cell survival.

• Multiple peer-reviewed studies confirm long-term survival and function of hypoimmune cells in non-human primates and humanized mice.

• First-in-human trial with HIP islet cells met all safety and efficacy endpoints, with no immune response detected at 12 months.

• Imaging and C-peptide data confirm graft survival and endogenous insulin production up to 14 months post-transplant.

In vivo CAR T cell platform and fusosome technology

• Fusosome technology enables cell-specific, in vivo delivery of CAR constructs, eliminating the need for conditioning chemotherapy.

• Preclinical studies show potent, specific transduction of CD8+ T cells with no off-target effects in non-human primates.

• Next-generation vectors (SG293, SG227) improve potency, specificity, and manufacturability, with demonstrated B cell depletion in vivo.

• SG293 is advancing to first-in-human trials for non-Hodgkin lymphoma, with potential expansion to autoimmune diseases and multiple myeloma.